Evaluating Pharmacokinetic Profiles of Mitomycin-C Regimens in Hyperthermic Intraperitoneal Chemotherapy
Researchers compared three distinct mitomycin-C dosing regimens for hyperthermic intraperitoneal chemotherapy using a rat model, finding differences in plasma levels but similar peritoneal concentrations.
Key points
- Compared three mitomycin-C HIPEC regimens in a rat model
- Group 1 demonstrated lower plasma concentrations with divided dosing
- Peritoneal-to-plasma AUC ratios showed no significant differences
A team of researchers has evaluated the pharmacokinetic properties of three different mitomycin-C (MMC) regimens utilized in hyperthermic intraperitoneal chemotherapy (HIPEC), a treatment approach frequently applied for colorectal peritoneal metastases. The experimental study utilized eighteen male Sprague–Dawley rats, which were randomized into three distinct groups for a 90-minute procedure at 41–42℃. Group 1 was given 35 mg/m² divided into three doses at 0, 30, and 60 minutes; Group 2 received 40 mg/m² split into two doses at 0 and 60 minutes; and Group 3 was administered a single bolus dose of 35 mg/m² at the start of perfusion. Investigators measured both peritoneal fluid and plasma concentrations using liquid chromatography-tandem mass spectrometry.
The findings indicate that MMC concentrations varied significantly across the three protocols over the 90-minute perfusion period. However, final peritoneal concentrations at the 90-minute mark remained comparable among the cohorts, registering at 73.63, 75.92, and 79.58 ng/mL respectively. Notably, plasma concentration was lower in Group 1 at 1.59 ng/mL compared to 2.45 and 2.02 ng/mL in the other groups. The peritoneal-to-plasma area under the curve (AUC) ratios showed no statistically significant divergence across the regimens. Experts note that animal model studies represent early-stage investigations, and caution that these pharmacological findings cannot be directly extrapolated to human clinical practices without further human trials.
What to know: While divided dosing schedules may lower systemic plasma exposure of mitomycin-C during HIPEC, peritoneal levels and overall AUC ratios remained similar across the tested methods. Always consult a qualified medical professional for guidance regarding cancer treatments and surgical protocols.
Source Nature Health Sciences — nature.com/articles/s41598-026-80723-7 ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.